Eli Lilly and Company (LLY)

FairStock Score: 61/100 — STEADY

Key Financials

Strengths

• Fortress margins: 34.4% net margin in Q4 2025 demonstrates pricing power in diabetes/obesity categories
• High-quality market: GLP-1 segment (Mounjaro) addresses $100B+ obesity and diabetes markets with secular tailwinds
• Exceptional returns: 101% ROE and 19.4% ROCE indicate efficient capital deployment and durable competitive advantages
• Defensive characteristics: 0.43 beta and essential pharmaceutical products provide recession resilience
• Strong cash generation: $2B annual free cash flow supports dividend and R&D investment

Concerns

• Extreme valuation disconnect: P/E of 39.5x and EV/EBITDA of 81x leave zero margin of safety; Graham Number is $70 vs. $1,008 price
• Deteriorating F-Score: Piotroski score of 6/9 signals weakening operational fundamentals and quality metrics
• Elevated leverage: 1.65 D/E ratio finances premium valuation; vulnerable if cash flows disappoint
• Growth opacity: N/A revenue and profit growth figures suggest possible deceleration or reporting anomalies; FCF yield of 0% indicates full valuation pricing in all upside

AI Analysis

Eli Lilly presents a fascinating paradox—exceptional business quality wrapped in a valuation that defies traditional Graham-Buffett principles. Let me be direct: at $1,008 per share with a Graham Number of $70, we're paying 14 times intrinsic value by classical standards. The margin of safety is essentially nonexistent. Yet, I cannot dismiss what I observe. This is a fortress business with a 34% net margin, 101% ROE, and genuine competitive moats anchored in diabetes and obesity treatments. Mounjaro and Basaglar command pricing power in massive, secular growth markets. The company generates $2B in free cash flow annually while commanding 0.43 beta—defensive during turbulence. The concerning signals are unmistakable. An EV/EBITDA of 81x is absurd, even for a quality compounder. The Piotroski F-Score of 6/9 suggests deteriorating fundamentals. High leverage (1.65 D/E ratio) finances this valuation structure—risky. Growth metrics show N/A, indicating potential deceleration or reporting gaps. Here's my honest assessment: Eli Lilly is an excellent business at a terrible price. The GLP-1 market opportunity is real and substantial, but current valuation assumes perfection for a decade. A 40% correction wouldn't surprise me. I'd rather wait for this exceptional compounder to stumble into the $600-700 range, where the margin of safety returns and I can sleep soundly. Quality at any price remains the enemy of intelligent investing.

Bull Case

Eli Lilly owns the dominant GLP-1 franchise in a $100B+ addressable market expanding 15-20% annually. Mounjaro's efficacy and market position create a decade-long secular tailwind, justifying premium valuations as the company compounds at 15%+ rates. Patent moats and manufacturing scale ensure sustained pricing power and margin expansion.

Bear Case

At 81x EV/EBITDA, Lilly prices in perfection. Competition from Novo Nordisk, regulatory pressures on drug pricing, and potential GLP-1 market saturation could trigger a sharp multiple compression. High leverage amplifies downside risk if growth disappoints or macro headwinds emerge.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer